BRAF and metastatic melanoma: Specifically vemurafenib or dabrafenib either as single agents or in combination with the MEK‐inhibitors cobimetinib or trametinib, produced objective response rates between 50% and 70%, and improved median progression‐free and overall survival in patients with BRAF‐mutant advanced or metastatic melanoma, leading to their FDA‐approvals 18, 19, 20, 21, 22.